Loading...

Ross Okimoto, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Phone--
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    2019American Society of Clinical Investigation Young Physician-Scientist Award
    2018NIH-NCI Career Development Award (K08)
    2018UCSF DOM Cohort Iniative Award
    2015A.P. Giannini Postdoctoral Fellowship

    Collapse Overview 
    Collapse Overview
    Dr. Okimoto is a medical oncologist who specializes in the treatment of bone and soft-tissue sarcomas. He is a laboratory based physician-scientist who broadly aims to translate basic science discoveries into novel therapies for patients with cancer. He is currently interested in understanding the molecular mechanisms that promote tumor dissemination and metastasis.

    Collapse Research 
    Collapse Research Activities and Funding
    Therapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasis
    NIH/NCI K08CA222625Feb 1, 2018 - Jan 31, 2023
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Global Health
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Capicua in Human Cancer. Trends Cancer. 2020 Sep 22. Kim JW, Ponce RK, Okimoto RA. PMID: 32978089.
      View in: PubMed   Mentions:    Fields:    
    2. Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma. Proc Natl Acad Sci U S A. 2020 Aug 11. Lin YK, Wu W, Ponce RK, Kim JW, Okimoto RA. PMID: 32788348.
      View in: PubMed   Mentions:    Fields:    
    3. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. J Clin Invest. 2019 07 22; 129(8):3401-3406. Okimoto RA, Wu W, Nanjo S, Olivas V, Lin YK, Ponce RK, Oyama R, Kondo T, Bivona TG. PMID: 31329165.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    4. Nuclear TARBP2 Drives Oncogenic Dysregulation of RNA Splicing and Decay. Mol Cell. 2019 09 05; 75(5):967-981.e9. Fish L, Navickas A, Culbertson B, Xu Y, Nguyen HCB, Zhang S, Hochman M, Okimoto R, Dill BD, Molina H, Najafabadi HS, Alarcón C, Ruggero D, Goodarzi H. PMID: 31300274.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    5. Metastasis: From head to tail. Cell Cycle. 2017 03 19; 16(6):487-488. Okimoto RA, Bivona TG. PMID: 28055306.
      View in: PubMed   Mentions:
    6. Inactivation of Capicua drives cancer metastasis. Nat Genet. 2017 01; 49(1):87-96. Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG. PMID: 27869830.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    7. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016 11 22; 113(47):13456-13461. Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG. PMID: 27834212.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    8. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 09 28; 380(1):144-52. Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. PMID: 27343980.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    9. Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discov. 2016 Jan; 6(1):14-6. Okimoto RA, Bivona TG. PMID: 26747892.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    10. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. PMID: 26301689.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    11. AXL receptor tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer (Auckl). 2015; 6:27-34. Okimoto RA, Bivona TG. PMID: 28210148.
      View in: PubMed   Mentions:
    12. 77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL). Brain Pathol. 2015 Jan; 25(1):111-2. Okimoto RA, Perry A, Rubenstein JL. PMID: 25521182.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Recent advances in personalized lung cancer medicine. Per Med. 2014; 11(3):309-321. Okimoto RA, Bivona TG. PMID: 25506379.
      View in: PubMed   Mentions: 9     Fields:    
    14. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr Opin Hematol. 2011 Mar; 18(2):89-97. Okimoto RA, Van Etten RA. PMID: 21252655.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    15. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 2008 May 01; 111(9):4716-22. Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA. PMID: 18299447.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    16. Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. Cancer Res. 2006 Oct 15; 66(20):10153-61. Hur J, Bell DW, Dean KL, Coser KR, Hilario PC, Okimoto RA, Tobey EM, Smith SL, Isselbacher KJ, Shioda T. PMID: 17047080.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    17. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4283-7. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW. PMID: 16857803.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    18. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res. 2006 Apr 01; 66(7):3452-5. Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, Haber DA. PMID: 16585167.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    19. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006 Feb 14; 103(7):2316-21. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. PMID: 16461907.
      View in: PubMed   Mentions: 195     Fields:    Translation:HumansCells
    20. American founder mutation for Lynch syndrome. Prevalence estimates and implications. Cancer. 2006 Jan 15; 106(2):448-52. Lynch HT, de la Chapelle A, Hampel H, Wagner A, Fodde R, Lynch JF, Okimoto R, Clark MB, Coronel S, Trowonou A, Fu YX, Haynatzki GR, Gong G. PMID: 16353207.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    21. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. PMID: 16299242.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    22. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 2005 Dec; 37(12):1315-6. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA. PMID: 16258541.
      View in: PubMed   Mentions: 150     Fields:    Translation:Humans
    23. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005 Nov 01; 23(31):8081-92. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. PMID: 16204011.
      View in: PubMed   Mentions: 156     Fields:    Translation:HumansCTClinical Trials
    24. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005 May 24; 102(21):7665-70. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA. PMID: 15897464.
      View in: PubMed   Mentions: 256     Fields:    Translation:HumansCells
    25. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20; 350(21):2129-39. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. PMID: 15118073.
      View in: PubMed   Mentions: 3151     Fields:    Translation:HumansCells
    26. A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA. 2004 Feb 11; 291(6):718-24. Lynch HT, Coronel SM, Okimoto R, Hampel H, Sweet K, Lynch JF, Barrows A, Wijnen J, van der Klift H, Franken P, Wagner A, Fodde R, de la Chapelle A. PMID: 14871915.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    27. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet. 2003 May; 72(5):1088-100. Wagner A, Barrows A, Wijnen JT, van der Klift H, Franken PF, Verkuijlen P, Nakagawa H, Geugien M, Jaghmohan-Changur S, Breukel C, Meijers-Heijboer H, Morreau H, van Puijenbroek M, Burn J, Coronel S, Kinarski Y, Okimoto R, Watson P, Lynch JF, de la Chapelle A, Lynch HT, Fodde R. PMID: 12658575.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells